140 related articles for article (PubMed ID: 24388871)
21. Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer.
Dijkgraaf EM; Welters MJ; Nortier JW; van der Burg SH; Kroep JR
Curr Pharm Des; 2012; 18(25):3816-27. PubMed ID: 22591418
[TBL] [Abstract][Full Text] [Related]
22. MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway.
Dai C; Xie Y; Zhuang X; Yuan Z
Biomed Pharmacother; 2018 Aug; 104():763-770. PubMed ID: 29807226
[TBL] [Abstract][Full Text] [Related]
23. Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer.
Isobe A; Sawada K; Kinose Y; Ohyagi-Hara C; Nakatsuka E; Makino H; Ogura T; Mizuno T; Suzuki N; Morii E; Nakamura K; Sawada I; Toda A; Hashimoto K; Mabuchi S; Ohta T; Morishige K; Kurachi H; Kimura T
PLoS One; 2015; 10(2):e0118080. PubMed ID: 25658637
[TBL] [Abstract][Full Text] [Related]
24. The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.
Wang X; Ivan M; Hawkins SM
Gynecol Oncol; 2017 Nov; 147(2):481-487. PubMed ID: 28866430
[TBL] [Abstract][Full Text] [Related]
25. [The molecular biology of epithelial ovarian cancer].
Leary A; Pautier P; Tazi Y; Morice P; Duvillard P; Gouy S; Uzan C; Gauthier H; Balleyguier C; Lhommé C
Bull Cancer; 2012 Dec; 99(12):1161-73. PubMed ID: 23238064
[TBL] [Abstract][Full Text] [Related]
26. The JAK/STAT signaling cascade in gastric carcinoma (Review).
Khanna P; Chua PJ; Bay BH; Baeg GH
Int J Oncol; 2015 Nov; 47(5):1617-26. PubMed ID: 26398764
[TBL] [Abstract][Full Text] [Related]
27. Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells.
Nishimura R; Moriyama K; Yasukawa K; Mundy GR; Yoneda T
J Bone Miner Res; 1998 May; 13(5):777-85. PubMed ID: 9610741
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-6/interleukin-6 receptor complex promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells.
Xie Z; Tang S; Ye G; Wang P; Li J; Liu W; Li M; Wang S; Wu X; Cen S; Zheng G; Ma M; Wu Y; Shen H
Stem Cell Res Ther; 2018 Jan; 9(1):13. PubMed ID: 29357923
[TBL] [Abstract][Full Text] [Related]
29. Biological role and clinical implications of homeobox genes in serous epithelial ovarian cancer.
Miller KR; Patel JN; Ganapathi MK; Tait DL; Ganapathi RN
Gynecol Oncol; 2016 Jun; 141(3):608-615. PubMed ID: 26957480
[TBL] [Abstract][Full Text] [Related]
30. [The dualistic model and extraovarian origin theory of ovarian epithelial cancer].
Kong BH
Zhonghua Fu Chan Ke Za Zhi; 2013 Apr; 48(4):310-3. PubMed ID: 23902820
[No Abstract] [Full Text] [Related]
31. The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer.
Chen MW; Yang ST; Chien MH; Hua KT; Wu CJ; Hsiao SM; Lin H; Hsiao M; Su JL; Wei LH
Cancer Res; 2017 Apr; 77(8):1955-1967. PubMed ID: 28209618
[TBL] [Abstract][Full Text] [Related]
32. PTN signaling: Components and mechanistic insights in human ovarian cancer.
Sethi G; Kwon Y; Burkhalter RJ; Pathak HB; Madan R; McHugh S; Atay S; Murthy S; Tawfik OW; Godwin AK
Mol Carcinog; 2015 Dec; 54(12):1772-85. PubMed ID: 25418856
[TBL] [Abstract][Full Text] [Related]
33. IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer.
Yousefi H; Momeny M; Ghaffari SH; Parsanejad N; Poursheikhani A; Javadikooshesh S; Zarrinrad G; Esmaeili F; Alishahi Z; Sabourinejad Z; Sankanian G; Shamsaiegahkani S; Bashash D; Shahsavani N; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A
Tumori; 2019 Feb; 105(1):84-91. PubMed ID: 30021477
[TBL] [Abstract][Full Text] [Related]
34. Tissue factor-factor VIIa complex induces epithelial ovarian cancer cell invasion and metastasis through a monocytes-dependent mechanism.
Ma Z; Zhang T; Wang R; Cheng Z; Xu H; Li W; Wang Y; Wang X
Int J Gynecol Cancer; 2011 May; 21(4):616-24. PubMed ID: 21543928
[TBL] [Abstract][Full Text] [Related]
35. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
[TBL] [Abstract][Full Text] [Related]
36. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
Wang Y; Ma X; Yan S; Shen S; Zhu H; Gu Y; Wang H; Qin G; Yu Q
Cancer Res; 2009 Sep; 69(18):7302-10. PubMed ID: 19706767
[TBL] [Abstract][Full Text] [Related]
37. IL-6 Promotes FSH-Induced VEGF Expression Through JAK/STAT3 Signaling Pathway in Bovine Granulosa Cells.
Yang M; Wang L; Wang X; Wang X; Yang Z; Li J
Cell Physiol Biochem; 2017; 44(1):293-302. PubMed ID: 29132131
[TBL] [Abstract][Full Text] [Related]
38. Leptin receptor signaling via Janus kinase 2/Signal transducer and activator of transcription 3 impacts on ovarian cancer cell phenotypes.
Kumar J; Fang H; McCulloch DR; Crowley T; Ward AC
Oncotarget; 2017 Nov; 8(55):93530-93540. PubMed ID: 29212170
[TBL] [Abstract][Full Text] [Related]
39. Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
[TBL] [Abstract][Full Text] [Related]
40. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
Zhang N; Zeng Y; Du W; Zhu J; Shen D; Liu Z; Huang JA
Int J Oncol; 2016 Oct; 49(4):1360-8. PubMed ID: 27499357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
